LGT Fund Management Co Ltd. Increases Holdings in Immix Biopharma, Inc. $IMMX

LGT Fund Management Co Ltd. increased its position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) by 233.3% in the first quarter, HoldingsChannel reports. The firm owned 416,594 shares of the company’s stock after acquiring an additional 291,594 shares during the quarter. LGT Fund Management Co Ltd.’s holdings in Immix Biopharma were worth $3,795,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of IMMX. Allworth Financial LP purchased a new position in Immix Biopharma during the 4th quarter worth approximately $30,000. Mathes Company Inc. acquired a new stake in shares of Immix Biopharma in the fourth quarter worth $56,000. Balyasny Asset Management L.P. purchased a new position in shares of Immix Biopharma during the fourth quarter worth $67,000. Kera Capital Partners Inc. acquired a new position in Immix Biopharma during the fourth quarter valued at $68,000. Finally, Velan Capital Investment Management LP boosted its holdings in Immix Biopharma by 40.0% in the third quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company’s stock valued at $73,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Stock Performance

Shares of Immix Biopharma stock opened at $11.11 on Monday. Immix Biopharma, Inc. has a one year low of $1.94 and a one year high of $12.14. The company has a market cap of $604.51 million, a price-to-earnings ratio of -12.08 and a beta of 0.09. The business’s 50 day moving average price is $9.41 and its 200 day moving average price is $8.26.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. On average, analysts predict that Immix Biopharma, Inc. will post -0.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on IMMX shares. Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Mizuho increased their price target on shares of Immix Biopharma from $14.00 to $15.00 and gave the stock an “outperform” rating in a report on Monday, March 30th. Citizens Jmp reissued a “market outperform” rating and issued a $23.00 price objective on shares of Immix Biopharma in a report on Friday, March 27th. Morgan Stanley initiated coverage on shares of Immix Biopharma in a research note on Wednesday, March 25th. They set an “overweight” rating and a $20.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research note on Tuesday, April 21st. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Immix Biopharma has an average rating of “Moderate Buy” and a consensus price target of $20.67.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.